- Friday, 5 September
- Saturday, 6 September
- Sunday, 7 September
| General Session | |
| State-of-the-Art Lecture | |
| Symposium | |
| Special Lecture | |
| Workshop | |
| Industry Symposium |
| TIME | Friday, 5 September |
| 11.30 – 12.30 | Biocompatibles Symposium The histological and clinical impact of the treatment of HCC patients eligible for surgery with intra arterial, doxorubicin Drug-Eluting Beads* Lunch provided |
| 12.30 – 12.45 | Session Break |
| 12.45 – 13.00 | Opening Ceremony |
| 13.00 – 15.00 |
Risk factors in the pathogenesis of HCC
|
| 15.00 – 15.30 | Coffee and Networking Break |
| 15.30 – 16.15 | Clinical Lecture: Evidence-based outcomes in cancer research and HCC Chair: Scott Friedman (USA) Speaker: Barnett Kramer (USA) |
| 16.15 – 16.30 | Session Break |
| 16.30 – 18.00 | General Session 1: Treatment of HCC –Surgery and local ablation Chairs: Jacques Belghiti (France) Michael Abecassis, Chicago (USA)O-001 Outcome following salvage liver transplant for recurrent hepatocellular carcinoma after resection: analysis of the OPTN database Presenting author: Francis YaoO-002 Partial liver resection for HCC in patients with good liver function can challenge liver transplantation Presenting author: Jacques BelghitiO-003 Outcome after curative resection for huge (10cm or more) hepatocellular carcinoma and prognostic significance of gross classification Presenting author: Dai Hoon HanO-004 Interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis – wonder or woe? Presenting author: Stefan BreitensteinO-005 Predictive factors of distant recurrence and survival in 203 patients with cirrhosis child pugh a and hepatocellular carcinoma HCC (≤ 5cm) treated by radiofrequency ablation (RFA) Presenting author: Gisèle G. N. NkontchouO-006 Treatment of malignant liver tumors with percutaneous microwave ablation: experience with complications in 1136 patients Presenting author: Ping Liang |
| 18.00 – 18.15 | Session Break |
| 18.15 – 19.15 | Bayer Schering Pharma Symposium Forging partnerships in the management of Hepatocellular Carcinoma: multidisciplinary strategies to provide continuity of care* |
| 19.15 – 20.00 | Welcome Reception |
| TIME | Saturday, 6 September |
| 08.00 – 09.00 | Sirtex Symposium Expanding treatment options in HCC through Radioembolisation/SIRT* |
| 09.00 – 09.30 | IARC perspective: New concepts in the epidemiology of HCC Chair: Hashem El-Serag (USA) Speaker: Paolo Boffetta (France) |
| 09.30 – 09.45 | Session Break |
| 09.45 – 11.15 | General Session 2: Molecular pathogenesis (genomics) Chairs: Xin Wei Wang (USA) Peter Galle (Germany) O-007 Hepatocellular carcinoma with progenitor cell features: clinical and biological characterization Presenting author: Pippa Newell O-008 Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Presenting author: Yujin Hoshida |
O-009 Transcriptional regulation of micro-RNAs highly expressed in human HCCs
Presenting author: Natalia Pediconi
O-010 miRNA-based molecular classification of hepatocellular carcinoma
Presenting author: Sara Toffanin
O-011 Molecular profiles in human nonalcoholic steatohepatitis (NASH) – related hepatocellular carcinoma (HCC) assessed by whole genome bioarray hybridization
Presenting author: Flair José Carrilho
O-012 In vivo reptin silencing blocks hepatocellular carcinoma progression
Presenting author: Jean Rosenbaum11.15 – 11.45 Coffee and Networking Break11.45 – 12.30 Translational Lecture: Molecular pathology and HCC: from cell of origin to diagnosis
Chair: Masamichi Kojiro (Japan)
Speaker: Pierre Bedossa (France) 12.30 – 14.15 Poster Session and Lunch14.15 – 14.45 Forty years of research in HCC in South Africa
Chair: Morris Sherman (Canada)
Speaker: Michael Kew (South Africa) 14.45 – 16.15 General Session 3: Clinical trials in molecular therapies
Chairs: Didier Samuel (France)
Al Benson (USA) O-013 Phase 2 open-label study of brivanib alaninate in patients with hepatocellular carcinoma
Presenting author: Joong-Won Park
O-014 Determining the impact of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ecog performance status (PS) on sorafenib safety and efficacy in patients with advanced hepatocellular carcinoma (HCC): sharp trial subset analyses
Presenting author: Jean-Luc Raoul
O-015 Randomized, phase I and pharmacokinetic (PK) study of RAD001, a mTOR inhibitor, in patients (PTS) with advanced hepatocellular carcinoma (HCC)
Presenting author: Li-Tzong Chen
O-016 Small molecule antagonists of beta-catenin/Tcf4 complex inhibit the growth of HCC cells in vitro and in vivo
Presenting author: Wei Wei
O-017 Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters Presenting author: Sandrine J. Faivre
O-018 A phase I clinical trial of prodrug-activating gene therapy for patients with hepatocellular carcinoma
Presenting author: Bruno Sangro16.15 – 16.45 Coffee and Networking Break16.45 – 18.15 General Session 4: Signaling and novel targets
Chairs: Gregory J. Gores (USA)
Sheng-Long Ye (P.R. China) O-019 Transforming growth factor-beta gene expression signature predicts clinical outcome in cancer
Presenting author: Cedric COULOUARN
O-020 A gene signature enables to discriminate vascular invasion in patients with hepatocellular carcinoma
Presenting author: Beatriz Minguez
O-021 Identification of potential driver genes in hepatocellular carcinoma: mechanistic and clinical implications
Presenting author: Hyun Goo Woo
O-022 Bolstering hepatic cancer stem cells by Wnt/beta-catenin signaling
Presenting author: Xin Wei Wang
O-023 lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma
Presenting author: Lun-Xiu Qin
O-024 Specific oncogenic pathways are activated in the different hepatocellular adenoma subtypes of tumors
Presenting author: Sandra Rebouissou18.15 – 18.45 Emerging molecules in HCC
Chair: Adrian M. Di Bisceglie (USA)
Speaker: Melanie Thomas (USA) 18:45 – 21:15ILCA-Workshop:
Liver transplantation in HCC
Entering the era beyond Milan and UCSF criteria in OLT
Building the future in solid ground
Organisation:
Pierre-Alain Clavien, Switzerland
Vincenzo Mazzaferro, Italy
Introduction: Goals, controversial data, goal of the workshop
Speaker: Pierre-Alain Clavien, Switzerland
Topic 1: Extension on what basis?
- Morphological parameters of HCC (size, number and volume of the tumor)
Chairs: Rafik M Ghobrial, USA, Myron Schwartz,USA - UCSF / UCLA Criteria
Speaker: Francis Yao, USA - Oriental Criteria
Speaker: Masatoshi Makuuchi, Japan - Volume of the tumor
Speaker: Sven Jonas, Germany - Biological markers and surrogates implying tumor sampling
Chairs: Snorri Thorgeirsson, USA, Kim Olthoff, USA - Vascular invasion, Grading
Speaker: Eberhard Renner, Canada - DNA ploidy implying serum markers, PIVKA
Speaker: Hiroto Egawa, Japan
Topic 2: Precising end-points in the extension process
Chairs: Josep Llovet, Spain/USA, Stefan Breitenstein, Switzerland
- Limitation of technology and modern approach of pre-transplant staging
Speaker: Riccardo Lencioni, Italy - New model of prognostication: the “Metroticket caldulator”
Speaker: Vincenzo Mazzaferro, Italy
Topic 3: Should extended criteria be different between cadaveric and living donation?
Chairs: Jacques Belghiti, France and Jordi Bruix, Spain/USA
- YES
Speaker: Zakiyah Kadry, USA - NO
Speaker: Michael Abecassis, USA
Topic 4: Influence of pre-transplant downstaging on post-transplant outcome and prognostication
Chairs: Pierre-Alain Clavien, Switzerland, Didier Samuel, France
- Pre-transplant downstaging
Speaker: Beat Müllhaupt, Switzerland
Conclusion
Speaker: Vincenzo Mazzaferro, Italy
| TIME | Sunday, 7 September |
| 08.30 – 10.00 | General Session 5: Epidemiology and molecular diagnosis Chairs: Elizabeth M. Brunt (USA) Young Nyun Park (Korea) O-025 Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease – a national cohort study, 1978-2003 Presenting author: Rune Erichsen |
O-026 Burden of hepatocellular cancer in a national sample of patients with chronic hepatitis C
Presenting author: Fasiha Kanwal
O-027 Occurrence of hepatitis C-related hepatocellular carcinoma (HCC) in the absence of cirrhosis: results from the HALT-C trial
Presenting author: Adrian M. Di Bisceglie
O-028 Hepatocellular carcinoma associated to chronic hepatitis delta
Presenting author: Raffaella Romeo
O-029 Telomere shortening, micronuclei, and inactivation of p21 during human multistep hepatocarcinogenesis
Presenting author: Young Nyun Park
O-030 Hepatocytic differentiation in cholangiocellular carcinoma suggesting hepatic progenitor cell origin
Presenting author: Mina Komuta10.00 – 10.30 Coffee and Networking Break10.30 – 12.30
Loco-regional treatments in HCC
Chairs: Luigi Bolondi (Italy)
Byung Ihn Choi (Korea)
- Local ablation: state-of-the art
Riccardo Lencioni (Italy) - Chemoembolization: Eastern perspective
Kenichi Takayasu (Japan) - Internal radiation: review of phase II data
Riad Salem (USA) - Overview of evidence-based diagnosis and loco-regional management of HCC
Andrew Burroughs (UK)
12.30 – 14.00 General Session 6 : Medical treatments
Chairs: Andrew Zhu (USA)
Kwang-Hyub Han (Korea) O-031 A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma
Presenting author: Melanie B. Thomas
O-032 Efficacy and safety of sorafenib in asian patients with advanced hepatocellular carcinoma
Presenting author: Ann-Lii Cheng
O-033 Actual survival following chemoembolization for hepatocellular carcinoma in a US center: correlation with prognostic systems
Presenting author: Michael C. Soulen
O-034 Radiologic-pathologic correlation of treated HCC tumors with Y90 microspheres
Presenting author: Laura Kulik
O-035 Radioembolization with therasphere yttrium-90 glass microspheres for advanced hepatocellular carcinoma: a European pilot phase II study
Presenting author: Philip Hilgard
O-036 RE-188 Lipiodol therapy of hepatocellular carcinoma: results of a multinational study
Presenting author: Ajit K. Padhy14.00 Closing Remarks